info@3helix.com
Fibrotic Tumors in a Clinical Array of PDAC can be Selectively Identified and Monitored by Collagen Hybridizing Peptides
Pancreatic Ductal Adenocarcinoma (PDAC) poses a wide range of diagnosis and treatment challenges. First, PDAC is difficult to diagnose; by the time patients present symptoms, they most likely have an advanced form of the disease, and the diagnosis is typically fatal. Furthermore, PDAC symptoms are not specific, meaning the condition is often misdiagnosed.
PDAC, like some other cancers, is characterized by the fibrotic shell which fibroblasts create around the tumor, "hiding" the tumor from the immune system, detection methods, and some therapies. Collagen Hybridizing Peptides can target and visualize this fibrotic shell, keeping researchers more informed about the how PDAC progresses and giving them the ability to make earlier, life-saving diagnoses.
We have already shown that CHPs can target and identify fibrosis significantly faster and with more detail than alternative stains, and can recognize the disease at every stage including metastasis.
Such fluorescent staining could be useful in other lethal malignancies:
We highly recommend using our In Vivo CHPs to investigate these conditions
Thanks for subscribing!
This email has been registered!